Evidence map›Paper›PMID 36732528›Full record

ArticleScientific reports2023

Multimodal single-cell analyses of peripheral blood mononuclear cells of COVID-19 patients in Japan.

Yukie Kashima, Taketoshi Mizutani, Kaori Nakayama-Hosoya, Saya Moriyama, Takayuki Matsumura, Yoshihiro Yoshimura, Hiroaki Sasaki, Hiroshi Horiuchi, Nobuyuki Miyata, Kazuhito Miyazaki and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Yukie KashimaLaboratory of Functional Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa, Chiba, 277-8562, Japan.
Taketoshi MizutaniLaboratory of Functional Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa, Chiba, 277-8562, Japan.
Kaori Nakayama-HosoyaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Saya MoriyamaResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
Takayuki MatsumuraResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
Yoshihiro YoshimuraDepartment of Infectious Diseases, Yokohama Municipal Citizens' Hospital, Kanagawa, Japan.
Hiroaki SasakiDepartment of Infectious Diseases, Yokohama Municipal Citizens' Hospital, Kanagawa, Japan.
Hiroshi HoriuchiDepartment of Infectious Diseases, Yokohama Municipal Citizens' Hospital, Kanagawa, Japan.
Nobuyuki MiyataDepartment of Infectious Diseases, Yokohama Municipal Citizens' Hospital, Kanagawa, Japan.
Kazuhito MiyazakiDepartment of Infectious Diseases, Yokohama Municipal Citizens' Hospital, Kanagawa, Japan.
Natsuo TachikawaDepartment of Infectious Diseases, Yokohama Municipal Citizens' Hospital, Kanagawa, Japan.
Yoshimasa TakahashiResearch Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0001-6342-4087
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-3820-9542
Sumio SuganoInstitute of Kashiwa-No-Ha Omics Gate, Kashiwa, Chiba, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0003-3096-6749
Ai Kawana-TachikawaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Yutaka SuzukiLaboratory of Functional Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa, Chiba, 277-8562, Japan. ysuzuki@edu.k.u-tokyo.ac.jp.
National Institute of Infectious Diseases · JPYokohama Municipal Citizen's Hospital · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 continues to spread worldwide. Patients with COVID-19 show distinct clinical symptoms. Although many studies have reported various causes for the diversity of symptoms, the underlying mechanisms are not fully understood. Peripheral blood mononuclear cells from COVID-19 patients were collected longitudinally, and single-cell transcriptome and T cell receptor repertoire analysis was performed. Comparison of molecular features and patients' clinical information revealed that the proportions of cells present, and gene expression profiles differed significantly between mild and severe cases; although even among severe cases, substantial differences were observed among the patients. In one severely-infected elderly patient, an effective antibody response seemed to have failed, which may have caused prolonged viral clearance. Naïve T cell depletion, low T cell receptor repertoire diversity, and aberrant hyperactivation of most immune cell subsets were observed during the acute phase in this patient. Through this study, we provided a better understanding of the diversity of immune landscapes and responses. The information obtained from this study can help medical professionals develop personalized optimal clinical treatment strategies for COVID-19.

Indexed as

COVID-19AgedHumansJapanLeukocytes, MononuclearReceptors, Antigen, T-CellSARS-CoV-2Single-Cell AnalysisReceptors, Antigen, T-Cell

Identifiers

PMID36732528
PMCPMC9893982
OpenAlexW4318982281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.